EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC-ND 4.0

The effects of non-insulin anti-diabetic medications on the diabetic microvascular complications: a systematic review and meta-analysis of randomized clinical trials

Song Wen, Yue Yuan, Yanyan Li, Chenglin Xu, Lijiao Chen, Yishu Ren, Congcong Wang, Yanju He, Xiucai Li, Min Gong, Xinlu Yuan, Dongxiang Xu und 2 weitere

BMC Endocrine Disorders · 2025

DOI: 10.1186/s12902-025-01985-2 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift BMC Endocrine Disorders, 2025. Verfasst von Song Wen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai, 201399, China. 379295093@qq.com. Hauptthemen laut MEDLINE: Hypoglycemic Agents, Diabetic Angiopathies, Diabetic Nephropathies, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fudan Zhangjiang Clinical Medicine Innovation Fund Project, Integrated Traditional Chinese and Western Medicine, Fudan Good Practice Program of Teaching and Learning.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Although the onset and progression of diabetic microvascular complications are linked to glycemic control, various antihyperglycemic drugs with distinct treatment targets may positively impact microvascular lesions beyond their glucose-lowering effects. Therefore, this systematic review emphasizes the clinical therapeutic implications of non-insulin anti-diabetic medications for diabetic microvascular complications. METHODS: We retrieved published literature reporting randomized clinical trials (RCTs) on the effects of microvascular complications, including diabetic nephropathy (DN), diabetic peripheral neuropathy (DPN), and diabetic retinopathy (DR), from authenticated clinical databases: PubMed, Excerpta Medica database (EMBASE), and Web of Science. We synthesized data, including the continuous variable indices: estimated glomerular filtration rate (eGFR), urinary albumin to creatinine ratio (UACR), and urinary albumin excretion rate (UAE). Indices measuring cardiovascular autonomic neuropathy (CAN), vibration detection threshold (VDT), and retinal nerve fiber thickness (RNFL) were used to calculate microvascular effects. We also synthesized dichotomous variable indices, including the risks for DR and DPN. RESULTS: According to our analyses, there was sparse evidence strongly supporting that metformin (MET), Sulfonylurea (SUs), Repaglinide (Repa), or α-Glucosidase inhibitors (α-GIs) could benefit diabetic microvascular complications when adopted as monotherapy. Regardless of the no change in eGFR, two trials reporting Thiazolidinediones (TZDs) significantly reduced the UACR, while other clinical trials reported an increase in VDT and improvement in DR. Sodium glucose co-transporter inhibitors (SGLT-2i) and Glucagon-like peptide-1 receptor agonists (GLP-1RA) both showed protective effects in preventing eGFR decline, with only SGLT-2i demonstrating a significant reduction in UACR. A recent trial showed that Dipeptidyl Peptidase IV inhibitors (DPP-IVi) may potentially reduce the risk of DPN, while GLP-1RA did not prove to alter the measures of CAN and DPN. However, the SUSTAIN 6 trial revealed that Semaglutide may increase the risk of DR. CONCLUSION: Besides their anti-hyperglycemic properties, some currently reviewed medications may exhibit unique anti-microvascular abilities. Due to ambiguous and conflicting available results, more emerging or ongoing trials will address this issue and could benefit clinical strategies for personalized treatment practices. CLINICAL TRIAL NUMBER: Not applicable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypoglycemic AgentsDiabetic AngiopathiesDiabetic NephropathiesDiabetes Mellitus, Type 2Diabetic RetinopathyDiabetic NeuropathiesHumansRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

Diabetic microvascular complicationDiabetic nephropathyDiabetic neuropathyDiabetic retinopathyNon-insulin anti-diabetic medication

Substanzen

Hypoglycemic Agents

Autor:innen und Institutionen

  • Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai, 201399, China. 379295093@qq.com.
  • Fudan Zhangjiang Institute, Shanghai Pudong Hospital, Shanghai, China. 379295093@qq.com.
  • Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai, 201399, China.
  • Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai, 201399, China. zhouligang1n1@163.com.
  • Shanghai Key Laboratory of Vascular Lesions Regulation and Remodeling, Shanghai, 201399, China. zhouligang1n1@163.com.

Förderung

  • Fudan Zhangjiang Clinical Medicine Innovation Fund Project
  • Integrated Traditional Chinese and Western Medicine
  • Fudan Good Practice Program of Teaching and Learning

Zitieren

APA

Wen, S., Yuan, Y., Li, Y., Xu, C., Chen, L., Ren, Y., Wang, C., He, Y., Li, X., Gong, M., Yuan, X., Xu, D., Wang, C., & Zhou, L. (2025). The effects of non-insulin anti-diabetic medications on the diabetic microvascular complications: a systematic review and meta-analysis of randomized clinical trials. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-025-01985-2

Vancouver

Wen S, Yuan Y, Li Y, Xu C, Chen L, Ren Y, et al. The effects of non-insulin anti-diabetic medications on the diabetic microvascular complications: a systematic review and meta-analysis of randomized clinical trials. BMC Endocrine Disorders. 2025. doi:10.1186/s12902-025-01985-2

BibTeX
@article{Wen2025,
  author = {Wen, Song and Yuan, Yue and Li, Yanyan and Xu, Chenglin and Chen, Lijiao and Ren, Yishu and Wang, Congcong and He, Yanju and Li, Xiucai and Gong, Min and Yuan, Xinlu and Xu, Dongxiang and Wang, Chaoxun and Zhou, Ligang},
  title = {The effects of non-insulin anti-diabetic medications on the diabetic microvascular complications: a systematic review and meta-analysis of randomized clinical trials},
  journal = {BMC Endocrine Disorders},
  year = {2025},
  doi = {10.1186/s12902-025-01985-2}
}
Kostenlos starten →